Detalhe da pesquisa
1.
The TLR4 antagonist Eritoran protects mice from lethal influenza infection.
Nature
; 497(7450): 498-502, 2013 May 23.
Artigo
em Inglês
| MEDLINE | ID: mdl-23636320
2.
Effect of eritoran, an antagonist of MD2-TLR4, on mortality in patients with severe sepsis: the ACCESS randomized trial.
JAMA
; 309(11): 1154-62, 2013 Mar 20.
Artigo
em Inglês
| MEDLINE | ID: mdl-23512062
3.
A phase II, double-blind, placebo-controlled, ascending-dose study of Eritoran (E5564), a lipid A antagonist, in patients undergoing cardiac surgery with cardiopulmonary bypass.
Anesth Analg
; 104(2): 378-83, 2007 Feb.
Artigo
em Inglês
| MEDLINE | ID: mdl-17242095
4.
TLR4 antagonists for endotoxemia and beyond.
Curr Opin Investig Drugs
; 6(5): 496-502, 2005 May.
Artigo
em Inglês
| MEDLINE | ID: mdl-15912963
5.
Antagonism of in vivo and ex vivo response to endotoxin by E5564, a synthetic lipid A analogue.
J Endotoxin Res
; 8(6): 483-8, 2002.
Artigo
em Inglês
| MEDLINE | ID: mdl-12697095
6.
Inhibition of endotoxin response by synthetic TLR4 antagonists.
Curr Top Med Chem
; 4(11): 1147-71, 2004.
Artigo
em Inglês
| MEDLINE | ID: mdl-15279606
7.
Safety, pharmacokinetics and pharmacodynamics of four-hour intravenous infusions of eritoran in healthy Japanese and Caucasian men.
Innate Immun
; 18(6): 793-803, 2012 Dec.
Artigo
em Inglês
| MEDLINE | ID: mdl-22459966
8.
Phase I study of E7820, an oral inhibitor of integrin alpha-2 expression with antiangiogenic properties, in patients with advanced malignancies.
Clin Cancer Res
; 17(1): 193-200, 2011 Jan 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-21208908
9.
Continuous pharmacodynamic activity of eritoran tetrasodium, a TLR4 antagonist, during intermittent intravenous infusion into normal volunteers.
Innate Immun
; 14(6): 383-94, 2008 Dec.
Artigo
em Inglês
| MEDLINE | ID: mdl-19039062
10.
Influence of plasma cholesterol and triglyceride concentrations and eritoran (E5564) micelle size on its plasma pharmacokinetics and ex vivo activity following single intravenous bolus dose into healthy female rabbits.
Pharm Res
; 25(1): 176-82, 2008 Jan.
Artigo
em Inglês
| MEDLINE | ID: mdl-17849177
11.
Safety, pharmacokinetics, pharmacodynamics, and plasma lipoprotein distribution of eritoran (E5564) during continuous intravenous infusion into healthy volunteers.
Antimicrob Agents Chemother
; 48(9): 3233-40, 2004 Sep.
Artigo
em Inglês
| MEDLINE | ID: mdl-15328078
12.
Association of the endotoxin antagonist E5564 with high-density lipoproteins in vitro: dependence on low-density and triglyceride-rich lipoprotein concentrations.
Antimicrob Agents Chemother
; 47(9): 2796-803, 2003 Sep.
Artigo
em Inglês
| MEDLINE | ID: mdl-12936976
13.
Inhibition of endotoxin response by e5564, a novel Toll-like receptor 4-directed endotoxin antagonist.
J Pharmacol Exp Ther
; 304(3): 1093-102, 2003 Mar.
Artigo
em Inglês
| MEDLINE | ID: mdl-12604686
14.
Blocking of responses to endotoxin by E5564 in healthy volunteers with experimental endotoxemia.
J Infect Dis
; 187(4): 631-9, 2003 Feb 15.
Artigo
em Inglês
| MEDLINE | ID: mdl-12599080
15.
Extended in vivo pharmacodynamic activity of E5564 in normal volunteers with experimental endotoxemia [corrected].
J Pharmacol Exp Ther
; 308(1): 175-81, 2004 Jan.
Artigo
em Inglês
| MEDLINE | ID: mdl-14566003
16.
A novel class of endotoxin receptor agonists with simplified structure, toll-like receptor 4-dependent immunostimulatory action, and adjuvant activity.
J Pharmacol Exp Ther
; 300(2): 655-61, 2002 Feb.
Artigo
em Inglês
| MEDLINE | ID: mdl-11805229